Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Given Average Rating of “Reduce” by Analysts

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) has earned a consensus rating of “Reduce” from the eight ratings firms that are covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating and seven have issued a hold rating on the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $24.50.

A number of equities analysts recently commented on AMPH shares. Weiss Ratings cut shares of Amphastar Pharmaceuticals from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday, April 10th. Wells Fargo & Company reissued an “equal weight” rating and issued a $19.00 price target (down from $30.00) on shares of Amphastar Pharmaceuticals in a report on Thursday, May 14th. Jefferies Financial Group reissued a “hold” rating and issued a $22.00 price target (down from $30.00) on shares of Amphastar Pharmaceuticals in a report on Tuesday, April 21st. Needham & Company LLC reissued a “hold” rating on shares of Amphastar Pharmaceuticals in a report on Friday, May 8th. Finally, Barclays cut their price target on shares of Amphastar Pharmaceuticals from $30.00 to $23.00 and set an “equal weight” rating on the stock in a report on Wednesday, April 8th.

Amphastar Pharmaceuticals Price Performance

Shares of NASDAQ:AMPH opened at $19.10 on Thursday. The stock has a market cap of $842.12 million, a PE ratio of 11.51, a PEG ratio of 3.05 and a beta of 0.97. The company’s fifty day moving average is $20.11 and its 200 day moving average is $23.93. Amphastar Pharmaceuticals has a 52 week low of $16.65 and a 52 week high of $31.26. The company has a quick ratio of 2.82, a current ratio of 3.85 and a debt-to-equity ratio of 0.79.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last issued its earnings results on Thursday, May 7th. The company reported $0.42 EPS for the quarter, missing analysts’ consensus estimates of $0.70 by ($0.28). The business had revenue of $171.17 million during the quarter, compared to analysts’ expectations of $173.46 million. Amphastar Pharmaceuticals had a return on equity of 15.12% and a net margin of 11.00%. Research analysts anticipate that Amphastar Pharmaceuticals will post 2.93 earnings per share for the current year.

Institutional Investors Weigh In On Amphastar Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in AMPH. AQR Capital Management LLC grew its holdings in Amphastar Pharmaceuticals by 82.0% in the 1st quarter. AQR Capital Management LLC now owns 53,638 shares of the company’s stock worth $1,555,000 after acquiring an additional 24,167 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Amphastar Pharmaceuticals by 2.8% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,489 shares of the company’s stock worth $652,000 after acquiring an additional 613 shares during the last quarter. Intech Investment Management LLC grew its holdings in Amphastar Pharmaceuticals by 43.0% in the 1st quarter. Intech Investment Management LLC now owns 60,289 shares of the company’s stock worth $1,748,000 after acquiring an additional 18,133 shares during the last quarter. Arrowstreet Capital Limited Partnership bought a new stake in Amphastar Pharmaceuticals in the 2nd quarter worth $1,865,000. Finally, Invesco Ltd. grew its holdings in Amphastar Pharmaceuticals by 7.7% in the 2nd quarter. Invesco Ltd. now owns 386,971 shares of the company’s stock worth $8,885,000 after acquiring an additional 27,828 shares during the last quarter. Institutional investors own 65.09% of the company’s stock.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company headquartered in Rancho Cucamonga, California. Founded in 2004, Amphastar focuses on the development, manufacturing and commercialization of injectable and inhalation products. The company’s manufacturing facilities in California produce both generic and proprietary formulations designed to address urgent and chronic medical conditions.

Amphastar’s portfolio includes a range of injectable generics such as epinephrine, naloxone and lidocaine, serving hospital, emergency medical and retail pharmacy channels.